Select Publications

Conference Papers

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2021, 'UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.325

Harris CA; Ward RL; Daniels B; Pearson S, 2013, 'Do pharmaceutical claims accurately reflect oncology prescribing practice? Evidence from an Australian HER2+early breast cancer cohort ( HER2EBC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Diego, CA, presented at ASCO's Quality Care Symposium, San Diego, CA, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.100

Harris CA; Pearson S; Daniels B; Srasuebkul P; Ward RL, 2013, 'HER2-positive early breast cancer (HER2EBC): An Australian pattern of care study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, San Diego, CA, presented at ASCO's Quality Care Symposium, San Diego, CA, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.101

Pearson S; Srasuebkul P; Harris C; Ward RL; Dobbins TA; Harris C, 2010, 'Trastuzumab treatment outcomes according to concomitant chemotheray regimen: Overall survival of HER2+ metastatic breast cancer patients', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S187 - S187, presented at Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, 19 August 2010 - 22 August 2010, http://dx.doi.org/10.1002/pds


Back to profile page